FDA approves Pfizer and Arvinas’ Veppanu for certain ESR1-mutated advanced breast cancers
The Facts
- The FDA approved Veppanu, the breast cancer drug developed by Pfizer and Arvinas, on May 1.
- Veppanu is approved for adults with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with an ESR1 mutation.
- The approval applies to patients whose disease has progressed after at least one line of endocrine or hormone therapy.
- Patients must have the ESR1 mutation identified by an FDA-authorized test to be eligible for treatment.
- The FDA also approved Guardant360 CDx as a companion diagnostic to identify patients with ESR1-mutated breast cancer who may receive Veppanu.
- The FDA said its decision was based on the phase 3 VERITAC-2 trial, which enrolled 624 adults with ER-positive, HER2-negative advanced breast cancer.
- Multiple sources describe Veppanu as the first FDA-approved PROTAC, a type of protein degrader therapy, making the approval notable beyond this specific breast cancer subtype.
- The approval is limited to a specific subgroup of advanced breast cancer patients, so a remaining practical question is which patients will test positive for ESR1 mutations and qualify under the FDA-authorized diagnostic pathway.
Context
Who can receive Veppanu under the FDA approval?
The drug is approved for adults with ER-positive, HER2-negative advanced or metastatic breast cancer whose tumors have an ESR1 mutation and whose disease has progressed after at least one line of endocrine therapy Reuters,U.S. Food and Drug ….
Why does ESR1 testing matter here?
The FDA approval requires confirmation of an ESR1 mutation using an FDA-authorized test, and the agency also cleared Guardant360 CDx as a companion diagnostic to identify eligible patients Medscape,U.S. Food and Drug …,360Dx.
What makes this approval notable beyond one drug launch?
Several sources say Veppanu is the first FDA-approved PROTAC, a protein degrader therapy, so the decision is also a milestone for that drug-development approach Drugs.com,Healio,BioPharma Dive.
How left and right read it
The important development is that adults with a hard-defined form of advanced or metastatic breast cancer now have a new FDA-approved option after prior endocrine or hormone therapy has failed. But the approval is tightly tied to an FDA-authorized test, so who actually benefits will depend on whether patients are identified through that diagnostic pathway.
What stands out here is a regulator approving a genuinely new kind of therapy: Veppanu is described as the first FDA-approved PROTAC, and the decision was grounded in a phase 3 trial involving 624 adults. At the same time, the FDA kept the authorization narrow, limiting use to patients who meet specific disease and testing criteria.
The receipts — all 21 sources
Wire services (4)
Independent coverage (17)
Facts first. Then every angle.
The day’s biggest stories in one short brief — the facts everyone agrees on, then the competing values behind the headlines. Free in your inbox.